261 related articles for article (PubMed ID: 32461482)
1. Intravitreal bevacizumab for iatrogenic choroidal neovascular membrane following vitreoretinal surgery for retinal detachment.
Appanraj R; Duraiswamy H; Saravanan V; Manayath G; Venkatapathy N
Indian J Ophthalmol; 2020 Jun; 68(6):1201-1203. PubMed ID: 32461482
[TBL] [Abstract][Full Text] [Related]
2. Management of Choroidal Neovascular Membranes Associated with Choroidal Nevi.
Munie MT; Demirci H
Ophthalmol Retina; 2018 Jan; 2(1):53-58. PubMed ID: 31047303
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab in the management of choroidal neovascular membrane secondary to choroidal osteoma.
Narayanan R; Shah VA
Eur J Ophthalmol; 2008; 18(3):466-8. PubMed ID: 18465736
[TBL] [Abstract][Full Text] [Related]
4. Concurrent management of myopic choroidal neovascularization and rhegmatogenous retinal detachment with intravitreal antivascular endothelial growth factor during primary retinal detachment repair.
Saurabh K; Roy R; Thomas NR; Chowdhury M
Indian J Ophthalmol; 2018 Mar; 66(3):472-474. PubMed ID: 29480274
[TBL] [Abstract][Full Text] [Related]
5. Rebound inflammation after an intravitreal injection in Vogt-Koyanagi-Harada syndrome.
Ranjan R; Agarwal M
Indian J Ophthalmol; 2018 Jun; 66(6):863-865. PubMed ID: 29786006
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic Peripapillary Subretinal Neovascular Membrane in a Young Woman with Recurrence of the Lesion during Pregnancy after Treatment with Intravitreal Bevacizumab.
Al-Gharbi N; Al Abdulsalam O; Al Habash A
Middle East Afr J Ophthalmol; 2015; 22(2):245-8. PubMed ID: 25949086
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization due to Sorsby macular dystrophy.
Kapoor KG; Bakri SJ
J Ocul Pharmacol Ther; 2013 May; 29(4):444-7. PubMed ID: 23581613
[TBL] [Abstract][Full Text] [Related]
8. Variation in Visual Outcome to Anti-Vascular Endothelial Growth Factors in Choroidal Neovascular Membrane Developing in Eyes with Previously Untreated Versus Focal Laser-Treated Central Serous Chorioretinopathy.
Roy R; Saurabh K; Das D; Panigrahi PK; Das S; Pal SS; Jain A
Semin Ophthalmol; 2017; 32(6):781-786. PubMed ID: 27533737
[TBL] [Abstract][Full Text] [Related]
9. INFLAMMATORY CHOROIDAL NEOVASCULAR MEMBRANE: Long-Term Visual and Anatomical Outcomes After Intravitreal Anti-vascular Endothelial Growth Factor Therapy.
Dʼsouza P; Ranjan R; Babu U; Kanakath AV; Saravanan VR
Retina; 2018 Jul; 38(7):1307-1315. PubMed ID: 28520642
[TBL] [Abstract][Full Text] [Related]
10. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation.
Singh SR; Fung AT; Fraser-Bell S; Lupidi M; Mohan S; Gabrielle PH; Zur D; Iglicki M; M López-Corell P; Gallego-Pinazo R; Farinha C; Lima LH; Mansour AM; Casella AM; Wu L; Silva R; Uwaydat SH; Govindahari V; Arevalo JF; Chhablani J
Br J Ophthalmol; 2020 May; 104(5):678-683. PubMed ID: 31401554
[TBL] [Abstract][Full Text] [Related]
11. Peripheral choroidal neovascular membrane in a case of peripheral exudative hemorrhagic chorioretinopathy managed with combination therapy.
Takkar B; Roy S; Sodhi PK; Azad S; Bajwa GS
Int Ophthalmol; 2017 Apr; 37(2):429-431. PubMed ID: 27312539
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF therapy in a silicone oil-filled myopic eye with choroidal neovascularisation.
Chhablani J; Narayanan R
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25870215
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks.
Sachdev N; Vishwanathan K; Gupta V; Singh R; Gupta A
Indian J Ophthalmol; 2007; 55(6):457-8. PubMed ID: 17951904
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravitreal connective tissue growth factor neutralizing antibody on choroidal neovascular membrane-associated subretinal fibrosis.
Daftarian N; Rohani S; Kanavi MR; Suri F; Mirrahimi M; Hafezi-Moghadam A; Soheili ZS; Ahmadieh H
Exp Eye Res; 2019 Jul; 184():286-295. PubMed ID: 31029789
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Bevacizumab for Traumatic Choroidal Rupture.
Kim M; Kim JH; Seo Y; Koh HJ; Lee SC
Optom Vis Sci; 2015 Oct; 92(10):e363-7. PubMed ID: 26367340
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Ranibizumab for myopic choroidal neovascularization after pars plana vitrectomy and silicone oil tamponade.
Cascavilla ML; Querques G; Querques L; Codenotti M; Bandello F
Eur J Ophthalmol; 2013; 23(6):913-6. PubMed ID: 23813105
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
Chen E; Kaiser RS; Vander JF
Retina; 2007; 27(4):445-50. PubMed ID: 17420696
[TBL] [Abstract][Full Text] [Related]
20. Choroidal Osteoma with Choroidal Neovascular Membrane treated with Anti- vascular Endothelial Growth Factor: A Rare Case with Review of Literatures.
Dorji P; Lepcha NT; Thapa R
Nepal J Ophthalmol; 2021 Jul; 13(24):196-201. PubMed ID: 35996784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
